<DOC>
	<DOCNO>NCT00311636</DOCNO>
	<brief_summary>RATIONALE : Chemotherapy may cause early menopause premenopausal woman . Triptorelin may prevent happen . PURPOSE : This randomized phase III trial study triptorelin see well work prevent early menopause premenopausal woman receive chemotherapy stage I , stage II , stage III breast cancer remove surgery .</brief_summary>
	<brief_title>Triptorelin Preventing Early Menopause Premenopausal Women Who Are Receiving Chemotherapy Stage I , Stage II , Stage III Breast Cancer That Has Been Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate incidence chemotherapy-induced early menopause premenopausal woman undergo adjuvant chemotherapy combination v without triptorelin previously resect stage I-III breast cancer . Secondary - Compare toxicity adjuvant chemotherapy triptorelin v adjuvant chemotherapy alone . OUTLINE : This prospective , open-label , multicenter , randomize study . Patients randomize 1 2 treatment arm . - Arm I ( adjuvant chemotherapy alone ) : Patients receive adjuvant chemotherapy alone . - Arm II ( adjuvant chemotherapy triptorelin ) : Patients receive adjuvant chemotherapy triptorelin intramuscularly 1 week every 4 week duration chemotherapy . The last dose triptorelin give last course chemotherapy . Patients hormone-sensitive tumor resume ovarian function stop chemotherapy triptorelin restart triptorelin ovarian function suppress 2 year . Patients undergo menopausal status assessment , use follicle-stimulating hormone , luteinizing hormone , estradiol biochemical marker , baseline 3 , 6 , 9 , 12 month last course chemotherapy . After completion study treatment , patient follow 3 , 6 , 9 , 12 month . PROJECTED ACCRUAL : A total 280 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm breast cancer resect time original diagnosis Stage IIII disease Candidate 1 follow adjuvant chemotherapy regimen : FEC ( fluorouracil , epirubicin hydrochloride , cyclophosphamide ) every 21 28 day CMF ( cyclophosphamide , methotrexate , fluorouracil ) every 28 day A→CMF ( doxorubicin hydrochloride follow CMF ) EC→P ( epirubicin hydrochloride cyclophosphamide every 21 day follow paclitaxel every 21 day ) FEC→P ( FEC every 21 day follow paclitaxel every 21 day ) EC→D ( EC every 21 day follow docetaxel every 21 day ) AC ( doxorubicin hydrochloride cyclophosphamide ) every 21 day AC→P ( AC every 21 day follow paclitaxel every 21 day ) E→CMF ( epirubicin hydrochloride follow CMF every 28 day ) No evidence metastases localize distant recurrence Investigation exclude metastasis require suspicious manifestation Premenopausal , define presence active menstrual cycle normal menses within six week initiation chemotherapy Hormone receptor status specify PATIENT CHARACTERISTICS : Female No malignancy within past 5 year except basal cell squamous cell skin cancer adequately treat situ carcinoma cervix No history noncompliance medical regimen patient consider potentially unreliable Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy and/or radiotherapy cancer nonneoplastic disease No concurrent hormonal therapy except tamoxifen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>